NCT03764787

Combination of Hypofractionated Proton Therapy With Immunotherapy

A Phase I/II Study of Combination of Hypofractionated Proton Therapy With Immunotherapy

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Peking University First Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using hypofractionated proton radiation therapy in combination with immunotherapy(ie. Programmed cell death protein 1, also known as PD-1 antibody). Hypofractionation is a technique that delivers higher daily doses of radiation over a shorter period of time.

Detailed description

Hypofractionated radiotherapy (HFRT), also known as Stereotactic body radiation therapy (SBRT) or Stereotactic ablative radiotherapy (SABR), is a regular pattern of photon radiotherapy. HFRT could achieve comparable curative effect to surgery in variable type of tumor. With the development of proton radiotherapy technology, proton HFRT technique is available nowadays. However, proton HFRT technique is mainly effective in improving the local control rates. This study intends to observe the safety and efficacy of proton HFRT technique combined with immunotherapy in improving the overall anti-tumor effect.

Conditions

• Proton Therapy
• Immunotherapy

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Radiation+PD-1 Ab	combination of proton radiotherapy with PD-1 antibody

Timeline

• Start date: 2019-01-01
• Primary completion: 2021-01-01
• Completion: 2021-12-01
• First posted: 2018-12-05
• Last updated: 2018-12-05